Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis

ConclusionResults of this study confirm the heterogeneity of new ‐onset juvenile DM based on serum biomarker profiles. Patients with high serum levels of galectin‐9, CXCL 10, TNFR II, and galectin‐1 may respond suboptimally to conventional treatment, and may therefore benefit from more intensive monitoring and/or treatment.

Source: Arthritis and Rheumatology - May 28, 2020 Category: Rheumatology Authors: Judith Wienke, Lauren M. Pachman, Gabrielle A. Morgan, Joo Guan Yeo, Maria C. Amoruso, Victoria Hans, Sylvia S. M. Kamphuis, Esther P. A. H. Hoppenreijs, Wineke Armbrust, J. Merlijn Berg, Petra C. E. Hissink Muller, Kyra A. Gelderman, Thaschaw Tags: Original Article Source Type: research